Emerging drugs for urothelial carcinoma

Benjamin A. Gartrell, Guru Sonpavde

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Advanced urothelial carcinoma is associated with a poor prognosis. In the metastatic setting, the response rate to first-line, cisplatin-containing chemotherapy is high, but survival is poor. Second-line treatment options are limited. Advanced age at diagnosis and the presence of comorbidities often preclude treatment with cisplatin-containing regimens. Areas covered: This review addresses the current therapy of urothelial carcinoma, the unmet needs in treatment and the status of drug development in this disease. The molecular targets identified and efforts to incorporate targeted agents into therapy will be addressed. Expert opinion: There have been no major advances in the treatment of urothelial carcinoma in three decades. Despite high response rates in the first-line setting, survival is limited. Major impediments to improved outcomes include poor durability of response to first-line chemotherapy and lack of second-line treatments. Better understanding in tumor biology has identified multiple targets in urothelial carcinoma; however, such discoveries have yet to lead to the incorporation of targeted agents into the routine treatment of urothelial carcinoma. Multiple ongoing clinical trials are investigating the use of targeted agents in urothelial carcinoma. Continued efforts are underway to better understand the molecular drivers of disease and such efforts are likely to identify additional therapeutic targets.

Original languageEnglish (US)
Pages (from-to)477-494
Number of pages18
JournalExpert Opinion on Emerging Drugs
Volume18
Issue number4
DOIs
StatePublished - Dec 2013

Fingerprint

Carcinoma
Pharmaceutical Preparations
Therapeutics
Cisplatin
Drug Therapy
Expert Testimony
Comorbidity
Clinical Trials
Neoplasms

Keywords

  • Bladder cancer
  • Molecular targets
  • Targeted therapy
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging drugs for urothelial carcinoma. / Gartrell, Benjamin A.; Sonpavde, Guru.

In: Expert Opinion on Emerging Drugs, Vol. 18, No. 4, 12.2013, p. 477-494.

Research output: Contribution to journalArticle

Gartrell, Benjamin A. ; Sonpavde, Guru. / Emerging drugs for urothelial carcinoma. In: Expert Opinion on Emerging Drugs. 2013 ; Vol. 18, No. 4. pp. 477-494.
@article{a06a7bf4e3e74bc7955fe394df675108,
title = "Emerging drugs for urothelial carcinoma",
abstract = "Introduction: Advanced urothelial carcinoma is associated with a poor prognosis. In the metastatic setting, the response rate to first-line, cisplatin-containing chemotherapy is high, but survival is poor. Second-line treatment options are limited. Advanced age at diagnosis and the presence of comorbidities often preclude treatment with cisplatin-containing regimens. Areas covered: This review addresses the current therapy of urothelial carcinoma, the unmet needs in treatment and the status of drug development in this disease. The molecular targets identified and efforts to incorporate targeted agents into therapy will be addressed. Expert opinion: There have been no major advances in the treatment of urothelial carcinoma in three decades. Despite high response rates in the first-line setting, survival is limited. Major impediments to improved outcomes include poor durability of response to first-line chemotherapy and lack of second-line treatments. Better understanding in tumor biology has identified multiple targets in urothelial carcinoma; however, such discoveries have yet to lead to the incorporation of targeted agents into the routine treatment of urothelial carcinoma. Multiple ongoing clinical trials are investigating the use of targeted agents in urothelial carcinoma. Continued efforts are underway to better understand the molecular drivers of disease and such efforts are likely to identify additional therapeutic targets.",
keywords = "Bladder cancer, Molecular targets, Targeted therapy, Urothelial carcinoma",
author = "Gartrell, {Benjamin A.} and Guru Sonpavde",
year = "2013",
month = "12",
doi = "10.1517/14728214.2013.853741",
language = "English (US)",
volume = "18",
pages = "477--494",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Emerging drugs for urothelial carcinoma

AU - Gartrell, Benjamin A.

AU - Sonpavde, Guru

PY - 2013/12

Y1 - 2013/12

N2 - Introduction: Advanced urothelial carcinoma is associated with a poor prognosis. In the metastatic setting, the response rate to first-line, cisplatin-containing chemotherapy is high, but survival is poor. Second-line treatment options are limited. Advanced age at diagnosis and the presence of comorbidities often preclude treatment with cisplatin-containing regimens. Areas covered: This review addresses the current therapy of urothelial carcinoma, the unmet needs in treatment and the status of drug development in this disease. The molecular targets identified and efforts to incorporate targeted agents into therapy will be addressed. Expert opinion: There have been no major advances in the treatment of urothelial carcinoma in three decades. Despite high response rates in the first-line setting, survival is limited. Major impediments to improved outcomes include poor durability of response to first-line chemotherapy and lack of second-line treatments. Better understanding in tumor biology has identified multiple targets in urothelial carcinoma; however, such discoveries have yet to lead to the incorporation of targeted agents into the routine treatment of urothelial carcinoma. Multiple ongoing clinical trials are investigating the use of targeted agents in urothelial carcinoma. Continued efforts are underway to better understand the molecular drivers of disease and such efforts are likely to identify additional therapeutic targets.

AB - Introduction: Advanced urothelial carcinoma is associated with a poor prognosis. In the metastatic setting, the response rate to first-line, cisplatin-containing chemotherapy is high, but survival is poor. Second-line treatment options are limited. Advanced age at diagnosis and the presence of comorbidities often preclude treatment with cisplatin-containing regimens. Areas covered: This review addresses the current therapy of urothelial carcinoma, the unmet needs in treatment and the status of drug development in this disease. The molecular targets identified and efforts to incorporate targeted agents into therapy will be addressed. Expert opinion: There have been no major advances in the treatment of urothelial carcinoma in three decades. Despite high response rates in the first-line setting, survival is limited. Major impediments to improved outcomes include poor durability of response to first-line chemotherapy and lack of second-line treatments. Better understanding in tumor biology has identified multiple targets in urothelial carcinoma; however, such discoveries have yet to lead to the incorporation of targeted agents into the routine treatment of urothelial carcinoma. Multiple ongoing clinical trials are investigating the use of targeted agents in urothelial carcinoma. Continued efforts are underway to better understand the molecular drivers of disease and such efforts are likely to identify additional therapeutic targets.

KW - Bladder cancer

KW - Molecular targets

KW - Targeted therapy

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84888866929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888866929&partnerID=8YFLogxK

U2 - 10.1517/14728214.2013.853741

DO - 10.1517/14728214.2013.853741

M3 - Article

C2 - 24195728

AN - SCOPUS:84888866929

VL - 18

SP - 477

EP - 494

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 4

ER -